sintilimab + cisplatin + paclitaxel albumin bound + carboplatin

This is a combination regimen consisting of four agents: - **Sintilimab** is a fully human IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor. It blocks the interaction between PD-1 and its ligands, thereby reactivating T cells and enhancing anti-tumor immunity[5][6][7][8]. - **Cisplatin** is a platinum-based chemotherapy agent that forms DNA crosslinks, leading to apoptosis in rapidly dividing cancer cells[2]. - **Paclitaxel albumin bound** (nab-paclitaxel) is a nanoparticle albumin-bound formulation of paclitaxel, which stabilizes microtubules and inhibits cell division. - **Carboplatin** is another platinum-based chemotherapeutic that induces DNA damage through crosslinking. This combination has been studied as first-line therapy for advanced squamous non-small cell lung cancer (sq-NSCLC), with evidence showing encouraging progression-free survival and tolerability when used together, particularly sintilimab with nab-paclitaxel/carboplatin[1]. The regimen leverages both immunotherapy (sintilimab) and cytotoxic chemotherapy (cisplatin, nab-paclitaxel, carboplatin) for synergistic anti-tumor effects.